Overview

Study to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer

Status:
Not yet recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
The study aims to demonstrate the preventive effect of DWP14012 20 mg for peptic ulcer is non-inferior to that of Lansoprazole 15 mg in terms of prevention of peptic ulcer and confirm the safety of DWP14012 20 mg.
Phase:
Phase 3
Details
Lead Sponsor:
Daewoong Pharmaceutical Co. LTD.
Treatments:
Dexlansoprazole
Lansoprazole